The promise of TRK inhibitors in pediatric cancers with NTRK fusions

Kinase drug discovery 20 years after imatinib: progress and future directions

(2021) Philip Cohen et al.   NATURE REVIEWS DRUG DISCOVERY

Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.

(2021) Sébastien Perreault et al.   JOURNAL OF CLINICAL ONCOLOGY

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

(2020) David S Hong et al.   LANCET ONCOLOGY

Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.

(2020) Alexander E. Drilon et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers

(2020) Tingting Jiang et al.   Acta Pharmaceutica Sinica B

Comment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020

(2020) Thomas Richard William Oliver et al.   BRITISH JOURNAL OF CANCER

HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS

(2020) Giles Robinson et al.   NEURO-ONCOLOGY

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

(2019) Giles W. Robinson et al.   JOURNAL OF CLINICAL ONCOLOGY

Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.

(2019) Cornelis Martinus van Tilburg et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

(2019) Emiliano Cocco et al.   NATURE MEDICINE

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

(2018) Theodore W Laetsch et al.   LANCET ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Use of Neoadjuvant Larotrectinib in the Management of Children With Locally Advanced TRK Fusion Sarcomas

(2018) Steven G. DuBois et al.   CANCER

Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application

(2018) Wei Yan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

(2018) Alexander Drilon et al.   Cancer Discovery

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy

(2017) Alanna J Church et al.   MODERN PATHOLOGY

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions

(2017) Pierre Vanden Borre et al.   ONCOLOGIST

Infantile NTRK-associated Mesenchymal Tumors

(2017) Jessica L Davis et al.   PEDIATRIC AND DEVELOPMENTAL PATHOLOGY

Identification of NTRK fusions in pediatric mesenchymal tumors

(2017) Dean Pavlick et al.   PEDIATRIC BLOOD & CANCER

Congenital mesoblastic nephroma 50 years after its recognition: A narrative review

(2017) S. L. Gooskens et al.   PEDIATRIC BLOOD & CANCER

ETV6 -NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study

(2017) Christian Vokuhl et al.   PEDIATRIC BLOOD & CANCER

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

(2017) Alexander Drilon et al.   Cancer Discovery

What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)

(2016) A. Drilon et al.   ANNALS OF ONCOLOGY

NTRKfusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States

(2016) Manju L. Prasad et al.   CANCER

Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience

(2016) Daniel Orbach et al.   EUROPEAN JOURNAL OF CANCER

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

(2016) Maria Menichincheri et al.   JOURNAL OF MEDICINAL CHEMISTRY

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

(2016) E. Ardini et al.   MOLECULAR CANCER THERAPEUTICS

Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay

(2016) Jennifer L. Picarsic et al.   PEDIATRIC AND DEVELOPMENTAL PATHOLOGY

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

FDA-approved small-molecule kinase inhibitors

(2015) Peng Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

(2015) M. Russo et al.   Cancer Discovery

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

(2015) R. C. Doebele et al.   Cancer Discovery

Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases

(2014) Sandra W Cowan-Jacob et al.   Future Medicinal Chemistry

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma

(2014) Gang Wu et al.   NATURE GENETICS

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

(2014) Thomas Wiesner et al.   Nature Communications

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

(2014) Aria Vaishnavi et al.   Cancer Discovery

Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy

(2013) Roshan Sethi et al.   LARYNGOSCOPE

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

(2013) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secretory carcinoma of the breast: Results from the survival, epidemiology and end results database

(2012) David P. Horowitz et al.   BREAST

Management of Unusual Histological Types of Breast Cancer

(2012) K. A. Cadoo et al.   ONCOLOGIST

Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group

(2011) K. J. Cohen et al.   NEURO-ONCOLOGY

Oncogenic Alterations in Papillary Thyroid Cancers of Young Patients

(2011) Geneviève Sassolas et al.   THYROID

Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity

(2010) Alena Skálová et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Pediatric Low-Grade Gliomas

(2009) Angela J. Sievert et al.   JOURNAL OF CHILD NEUROLOGY

Infantile Fibrosarcoma: Management Based on the European Experience

(2009) Daniel Orbach et al.   JOURNAL OF CLINICAL ONCOLOGY

Cellular mesoblastic nephroma (infantile renal fibrosarcoma): institutional review of the clinical, diagnostic imaging, and pathologic features of a distinctive neoplasm of infancy

(2009) Petek Bayindir et al.   PEDIATRIC RADIOLOGY